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Abstract:  
Objective: To determine the incidence and predictors of negative large loop excision of the 
transformation zone (LLETZ) following the introduction of Human papillomavirus (HPV) cervical 
screening. 
Method: A retrospective cohort study. Two independent cohorts, who attended for a LLETZ 
procedure, before and after the introduction of HPV cervical screening were compared. For each 
cohort, 401 individuals were randomly selected from a colposcopy database. Clinical and colposcopic 
variables were extracted. The incidence of negative LLETZ was estimated in each cohort. Regression 
analysis was used to adjust for potential confounders and explore predictors of negative LLETZ. 
Results: Eighty women (19.9%) from the pre-HPV testing cohort and 54 women (13.4%) from the 
post-HPV cohort were negative for cervical intraepithelial neoplasia (RR 0.75, CI: 0.55 to 0.93). In the 
post-HPV testing cohort, independent predictors of negative LLETZ were low grade cytology (RR 
3.60, CI: 2.18-5.97) and a type 3 transformation zone (TZ) (RR 2.88, CI: 1.76-4.72). Women with both 
low grade cytology and a TZ type 3 were 8.6 times more likely to have a negative LLETZ (absolute risk 
40%, 95% CI: 27-54%).  
Conclusions: Despite a 25% reduction in negative LLETZ following the introduction of HPV cervical 
screening, the incidence is still high. These results highlight the importance of continuing to improve 
the specificity of cervical intraepithelial neoplasia screening; this should include the use of 
biomarkers that detect HPV transforming infections and techniques that sample an entirely 
endocervical transformation zone. 
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Introduction: 
Loop excision of the cervical transformation zone (LLETZ) has helped reduce the overall mortality 
rate from cervical cancer by 60% in the UK through excision of the precursor lesion, cervical 
intraepithelial neoplasia (CIN).1,2 Recent evidence however has suggested that depth of excised 
tissue proportionally increases the risk of preterm labour3. Furthermore, LLETZ has been shown to 
increase the risk of cervical stenosis which can cause infertility, amenorrhoea and difficulty with 
subsequent cytological assessments4,5. 
 
A negative LLETZ occurs when no CIN is identified in the histological specimen and the reported 
incidence in women with biopsy confirmed CIN2+ varies from 5.9% to 41%6-11. This large variation is 
secondary to differing criteria for treatment. Given that 56% of women referred to colposcopy in 
England are 25-35 years old, in prime reproductive age, and 12.9% of these referrals will result in a 
LLETZ12, a reduction in false positive cervical screening would potentially reduce unnecessary 
treatments and the risk of infertility or preterm labour. 
 
Human Papillomavirus (HPV) cervical screening was introduced in 2011 in six sentinel sites in the 
UK13 following the publication of randomised control trials which demonstrated that HPV DNA 
detection was a more sensitive screening test than cytology for squamous cell lesions (94.6% vs 
83.9%)14,15. Subsequently, there has been contradictory evidence regarding the potential effect of 
HPV screening on the mean rate of negative LLETZ (false positive screening). Women who are 
negative for high risk HPV phenotypes have been shown to have higher rates of negative LLETZ9-10. 
Moreover, HPV testing has been shown to increase the detection of low grade squamous lesions by 
failing to differentiate between transient and transforming infections15. 
The objectives of this study were to evaluate whether primary HPV DNA cervical screening has 
reduced the mean rate of negative LLETZ histology and to examine predictors of negative LLETZ after 
the introduction of HPV screening. 
 
Materials and methods; 
A retrospective, single centre, comparative cohort study was completed at University Hospitals 
Bristol NHS Foundation Trust (a sentinel site for primary HPV screening in the UK). Ethical approval 
was granted by the Southwest Cornwall and Plymouth National Research Ethics Committee (study 
number 14/SW/0127). 
 
Women 25–64 years old who had a LLETZ before the introduction of HPV screening (2008) and after 
the introduction (2011) were eligible for inclusion as two independent cohorts. Women outside of 
this age range are not eligible for cervical screening in England. Women who had a LLETZ during the 
Sentinel Sites Study (2008 – 2010)13 were excluded as Bristol was a pilot centre for HPV triage in the 
UK and management of these women, including frequency and type of follow up, was different to 
national protocols instituted after the publication of the study. Women in the pre-HPV testing cohort 
were referred to colposcopy for all grades of cytological abnormalities and referrals in the post-HPV 
testing cohort were for a HR-HPV positive test with subsequent cytology triage. HPV DNA testing was 
by Hybrid Capture 2 (HC2) which gives a pooled result of high risk subtypes but not individual 
genotyping. Women reviewed in colposcopy before the introduction of HPV cervical screening were 
not managed by HPV triage.  
 
A sample size calculation estimated 401 subjects would be needed in each cohort; assuming a 
negative LLETZ incidence of 14% (from Livasay et al7), a reduction in negative LLETZ of 50% (to 7%) 
following the introduction of HPV screening, with alpha at 0.05 and power at 90%. The incidence 
from Livasay et al was used as they reported the mean incidence of comparable studies and an 
effect size of 50% was based on the improved sensitivity of HPV testing. Although the specificity of 
HPV screening alone is poor in young women for detecting CIN2+ (76.5%)16, and therefore an 
increase in negative LLETZ may be anticipated, the women in the HPV testing cohort who were 
positive for HR HPV were triaged with cytology which increases the specificity to 95.6%.17 
 
Participants were randomly selected from a colposcopy database by an independent Information 
Analyst using ‘treatment type’ and ‘appointment date’ as search terms. Individuals were selected 
into the study on the basis of the exposure (whether or not they had had HPV screening), not the 
outcome, and as such a case control design would not have been appropriate. Therefore, potential 
confounders such as age, smoking status, parity and contraceptive use were recorded (smoking and 
parity increase the risk of CIN progression18,19). These data were divided into categories for ease of 
analysis: age into 30 years or less, 31-40, 41-50 and 51 years or more; contraceptive into none, 
oestrogen and progesterone excess (postmenopausal, use of Depoprovera, Implanon and the 
Mirena Coil); parity as none, one and more than two. To reduce transference errors and improve the 
quality of the data collection, double data entry was completed and a table of definitions was 
constructed to ensure the researchers entered the same field values. 
 
Pathology reports were reviewed for referral cytology, which was coded as Negative, Low grade or 
High Grade according to the revised 1986 BSCC Classification System20, and for HR HPV status; coded 
as negative or positive. Biopsy results and histological diagnosis at LLETZ were categorized as 
negative, CIN1, CIN2, CIN3, cGIN or invasive. Margin involvement, excision depth (coded as ≤ 6mm, 
7-10mm, ≥11mm) and limiting factors such as cautery effect, denudation or tubo-endometroid 
metaplasia were also recorded and coded as present or absent.  
The definition of a positive LLETZ was any histological specimen which contained CIN of any grade, 
cervical glandular intraepithelial neoplasia (cGIN) or cancer6-11. The definition of a negative LLETZ 
was a histological specimen in which there was no evidence of CIN; differentiating between transient 
and transforming HPV infections is problematic and specimens containing no CIN should be 
considered as true false positives. As part of routine practice, LLETZ samples reported as negative 
were reviewed independently by two consultant histopathologists and additional blocks processed 
to confirm the absence of CIN. For the study purposes, all cytological and histological follow up of 
the negative LLETZ women were recorded to validate the result. 
 
Differences in the incidence of negative LLETZ may have been affected by policy change rather than 
HPV testing and therefore variables that relate to this were collected. National guidelines in the UK21 
provide recommendations on intervals from cytological screening to colposcopic assessment, 
diagnostic standards for colposcopy and criteria for LLETZ. The indications for LLETZ were divided 
into those who had a biopsy prior to LLETZ (persistent CIN1 for greater than 24 months, CIN2 / 3 or 
cGIN) and those who had a see and treat LLETZ (no prior histology). Indications for see and treat 
LLETZ included a high grade cytology referral with confirmatory high grade colposcopic findings, a 
high grade cytology referral with a transformation zone type 3 or persistent (>12 months) low grade 
cytology with a transformation zone type 3. 
 
Clinical records and colposcopic images were assessed to confirm the position of the transformation 
zone (TZ) in relation to the endocervical canal; as specified by the IFCPC nomenclature, this was 
coded as a TZ type 1 or 2 when the squamocolumnar junction (SCJ) was fully or partially visible 
(satisfactory colposcopy) or a TZ type 3 when the SCJ could not be visualized (unsatisfactory 
colposcopy)22. The size of the lesion (coded out of four quadrants), the interval in weeks from 
cytology to colposcopy and from colposcopy to treatment (coded as 0-4 weeks, 5-8 and more than 
nine) and the management instituted (see and treat, biopsy, repeat cytology or conservative) were 
also recorded. 
 
Statistical methods: 
The incidence of negative LLETZ in the cohorts before and after HPV screening, were calculated 
along with the risk ratio and absolute risk difference. Confidence intervals and p-values for these risk 
statistics were estimated using the normal approximation. A set of Poisson regression models 
examined whether the association between the introduction of HPV screening and negative LLETZ 
was explained by differences in potential confounders between the two cohorts. We used a poisson 
regression rather than logistic model because a risk ratio is easier to interpret than an odds ratio 
when the prevalence of the outcome (negative LLETZ) is fairly high. Two models were estimated: the 
first adjusted for each of the potential confounders in turn and the second adjusted for all potential 
confounders. We also explored predictors of negative LLETZ in the HPV testing cohort. First, in 
unadjusted models we examined the association between each of the following with negative LLETZ; 
age, parity, contraceptive, cytology result, interval from cytology to colposcopy and TZ type and 
second, we included those variables where there was some evidence of an association with negative 
LLETZ (p<0.05). As a sensitivity analysis we also used a forward and backward model selection 
algorithm using cut offs for entry and removal of 0.05 and 0.1. All approaches resulted in the same 
final model. For all models we used robust standard errors to control for mild violations of the model 
assumptions. Stata v13.1 was used for all analyses. 
 
Results: 
All 802 women had complete data sets for the clinical and colposcopic variables collected. The 
majority of women were less than 30 years old, nulliparous, non-smokers, had a high grade cytology 
referral and a visible transformation zone. A full description of the clinical characteristics is given in 
Table 1. 
 
Compared to the pre-HPV cohort, more women in the post-HPV screening cohort were younger than 
30 and older than 50 years and more women used contraceptive. The two cohorts were similar with 
respect to parity, smoking habits, referral cytology, histological limiting factors and visibility of the 
TZ. However, in the pre-HPV cohort the interval from cytology to colposcopic assessment was longer 
(mean 7 weeks, SD 4.21 vs mean 5.4 weeks, SD 4.44; p<0.001) and more women had an excision 
depth less than 7mm (Table 1). The LLETZ histology for the two cohorts, as presented in Table 1, was 
similar with respect to CIN, cGIN and invasion.  
 
The criteria for LLETZ, as recommended by the NHSCSP publication no 2021, were compared between 
pre- and post-HPV testing cohorts (Table 1) and between women with a negative LLETZ result (Table 
2). In women with negative histology, the criteria for LLETZ, was similar between cohorts. 
 
Incidence of negative LLETZ in the two cohorts. 
The incidence of negative LLETZ was 19.9% (80/401) in the pre-HPV cohort and 13.4% (54/401) in 
the post-HPV screening cohort, giving an unadjusted relative risk of 0.68 (95% CI: 0.49 to 0.93); in 
Table 3. The largest confounder in Table 3 was the interval from cytology to colposcopy; after 
adjusting for this variable there was no evidence of an association between HPV screening and 
negative LLETZ (RR 0.83; 95% CI: 0.60 to 1.15). In the final fully adjusted model that controlled for 
differences in age, smoking, contraceptive use, parity, referral cytology, biopsy result prior to LLETZ 
and histological limiting factors, there was a 25% reduction in negative LLETZ in women who had had 
HPV screening. 
Table 4 shows the association of a range of patient and clinical variables with negative LLETZ among 
women who underwent HPV screening. Based on the final model, and after adjusting for parity, the 
risk of negative LLETZ from a TZ type 3 was shown to be independent of a low grade or high grade 
cytology referral. The marginal probability of negative LLETZ with high grade cytology, based on the 
final model in table 4 was 6% (0.06, 95% CI: 0.04 to 0.09). Among women with low grade cytology 
this was 23% (0.23, 95% CI: 0.09 to 0.21). The risk of negative LLETZ, however, was noted to be 
highest among women with low grade cytology and a TZ type 3 (RR 10.4, 95% CI: 5.9 to 18.4, 
p<0.001). It should be noted that while this risk is high in both relative and absolute terms (+40%; 
95% CI: 27 to 54%, p<0.001 based on an additive binomial model), only 22/401 (5.5%) women in our 
study had both low grade cytology and a TZ type 3. The risk of negative LLETZ was reduced among 
women who had confirmatory histology prior to LLETZ.  
 
The association between clinical variables and a TZ type 3 was explored. A strong positive linear 
relationship was found between increasing age (compared to women who were less than 30 years 
old; among 31 to 40 years RR 1.26, 95% CI 0.69 – 2.29, among 41 to 50 years RR 2.72, CI 1.57 – 4.73 
and age greater than 50 years RR 4.17, CI 2.41 – 7.21). Oestrogen use had a protective association 
compared to women who did not use any form of hormonal treatment (RR 0.25, CI 0.11 – 0.60), 
whilst progesterone use was not associated with a TZ type 3 (RR 0.93, CI 0.60 – 1.44). Lastly, there 
was weak evidence of an association between parity and a TZ type 3 (RR 0.66, 95% CI: 0.43 to 1.02, 
p=0.06). 
 
Cytological follow up in the negative LLETZ cohorts.  
In women who had HPV testing and negative LLETZ histology, follow up cytology was available for 45 
(nine had moved from the area). 35/45 were HPV negative six months after LLETZ and none 
developed dyskaryosis during the follow up period (mean 39.6 months, range 6 to 44 months). 4/45 
were HPV positive at their six month test of cure; one had CIN1 whilst the remainder had negative 
cytology during follow up (mean 30 months). 6/45 women had dyskaryosis at their 6 month test of 
cure, (two high grade and four low grade) of whom two had VAIN and the remainder had HPV (mean 
follow up 33 months, range 28 to 36 months). In the women who had a negative LLETZ prior to HPV 
testing, follow up cytology was available for 68. 7/68 women had dyskaryosis at their 6 month follow 
up, (one high grade and six low grade): two had VAIN, one cGIN, one CIN1 and three HPV (mean 
follow up 7 months, range 6 to 18 months). 61/68 had negative cytology six months after LLETZ, of 
whom ten developed dyskaryosis (all low grade) during the follow up period (mean 66 months, 
range 6 to 102 months). Three of the ten women women had VAIN, one CIN2 and the remainder 
HPV. In summary, 3/45 (6%) women developed positive histology (CIN1+) following a negative LLETZ 
in the HPV testing cohort and 8/68 (11.7%) in the cytology only cohort (RR 0.59, CI 0.16 to 2.12, 
p=0.53). 
 
Discussion: 
Negative LLETZ is an important performance indicator in colposcopy and quality management of a 
cervical screening programme. The current literature has focused on HPV screening test 
performance and referrals to colposcopy rather than ‘down line’ issues of overtreatment. Our results 
show, for the first time, that the incidence of negative LLETZ has decreased after the introduction of 
HPV cervical screening, but the prevalence of false positives is still high at 13.4%. Risk factors for 
negative LLETZ in the HPV testing cohort were a TZ type 3, low grade cytology and parity. Women 
with both low grade cytology and a TZ type 3 were most at risk.  
 
The reported incidence of negative LLETZ in women with biopsy confirmed CIN2+ varies from 5.9% 
to 41%6-11. The rates within our unit fall within this range. A histological diagnosis of CIN2 currently 
mandates treatment; regression or detection of early and therefore small lesions, which may have 
been removed after punch biopsy, could account for negative LLETZ histology. Our findings show 
that between negative LLETZ cohorts there was no difference in the criteria for treatment and 
support evidence that colposcopic assessment and confirmatory biopsies reduce the incidence of 
negative LLETZ10,11.  
 
Missing CIN during the treatment or when interpreting the histology could account for a negative 
LLETZ result. Rates of positive histology following a negative LLETZ (an indicator of residual disease) 
were compared between cohorts; our results showed that the 95% confidence interval for the 
relative risk included the null value of 1 and therefore there is insufficient evidence to conclude that 
the groups are statistically different. The negative histology samples were assessed by two 
independent histopathologists with extra levels to ensure that all cases met the inclusion criteria - 
indicating that the same proportion of CIN should be ‘missed’ between cohorts. Furthermore, 
variables such as referral cytology, limiting histological factors and inclusion of the transformation in 
the LLETZ sample were assessed and found to be similar between cohorts. 
 
The aim, following colposcopic assessment, is to treat high grade disease and allow low grade 
disease to resolve. If a TZ type 1 or 2 is present and CIN1 is detected, cytological follow up is 
recommended for 24 months13. The difficulty, as illustrated by our results, is when women present 
with a TZ type 3. The inability to visualise and histologically identify transforming infections deters 
conservative follow up. Moreover, a lack of national guidance in this cohort, combined with patient 
choice, may account for a higher rate of treatments in women with low grade cytology than 
anticipated.  
 
Colposcopists may rely on the diagnostic value of HPV screening in women with a type 3 TZ to 
determine who requires treatment. However, the HPV DNA test currently approved in the UK is 
Hybrid Capture 2 (HC2) which gives a pooled result of the high risk genotypes14. The inability of HC2 
to genotype the more aggressive subtypes, such as HPV 16 and 18 (which cause 70% of cervical 
cancers)23 and the poor specificity of HPV testing for low grade cytology (which is only 86.5%)14,24, 
could also be a factor in the observed rates of low grade LLETZ histology by increasing the risk of 
treating women who may have a transient HPV infection15.  
 
None the less, our results indicate that HPV testing has reduced the number of negative LLETZ 
specimens. HPV screening is a more sensitive cervical screening test than cytology alone for the 
detection of squamous cell lesions. Recent UK cervical cancer screening statistics have shown that 
since its introduction, the number of women referred with borderline or inadequate cytology and 
those with normal colposcopy has reduced. The overall proportion of women reviewed in 
colposcopy with CIN has increased, thereby decreasing the number with negative histology. It stands 
to reason that prior to HPV screening, women referred with false positive cytology would have been 
weeded out by a negative punch biopsy but women with unsatisfactory colposcopy and cytology 
reported as borderline ?high grade may have been offered treatment by anxious colposcopists, 
thereby increasing the rates of negative LLETZ. 
 
Regardless of the improved sensitivity of HPV screening, our findings have shown that women with 
unsatisfactory colposcopy and low grade cytology are still at increased risk of negative LLETZ. To 
reduce false positives, studies have evaluated mechanical and pharmacological methods of 
improving the adequacy of the colposcopic examination. Completing an assessment at specific times 
during the menstrual cycle was unsuccessful25. The use of systemic and topical oestrogen can 
improve the visibility of the SCJ26-27 but this practice has not been routinely adopted in the UK. This 
may be due to the side effect profile, contraindications, patient choice, patient compliance or cost of 
follow up appointments. Vaginal misoprostol has had varying success (20-78.9%)28 but patients 
report nausea, abdominal pain and fever. Hygroscopic cervical dilators have a reported success rate 
of 79-94%29, but women with a TZ type 3 were not included in these studies. Endocervical canal 
curettage can be used to obtain ~1mm3 samples of squamous epithelium from inside the cervical 
canal. However, the small and fragmented samples can lead to inadequacy rate of up to 19%30-32, the 
inter-observer agreement is at best moderate (k = 0.58; CI 0.52 – 0.63) and diagnosis can therefore 
be underestimated in 16-45% of squamous cell lesions.32-33  
 
In this study, double data entry and a complete data set for both cohorts removed bias caused by 
erroneous and missing data. To minimise residual confounding, variables which could explain the 
observed association between HPV testing and negative LLETZ, were collected and controlled for. 
HPV screening results and the colposcopic assessment were recorded before the LLETZ outcome was 
known and clinical data was prospectively documented, minimizing recall bias. Moreover, this study 
was specifically designed to address the research questions in this paper and as such, a sample size 
calculation along with the strict triage described above, helped ensure sufficient power.  
 
In the pre-HPV testing cohort photographic images were not taken as part of routine practice prior 
to LLETZ, preventing assessment of lesion size. However local policy advocated, in both cohorts, a 
strict selection criteria for treatment by recommending confirmatory biopsies if a significant change 
in lesion size and / or grading occurred. This comparative study uses historical controls and therefore 
it could be argued that the decrease in negative LLETZ histology could be associated with a change in 
clinical practice rather than the introduction of HPV screening. To address this, potential 
confounders were collected and controlled for. Moreover, following the results of the sentinel sites 
study it would be unethical to conduct a randomized control trial when high quality studies have 
shown that cytology alone has poorer sensitivity for detecting CIN than HPV cervical screening. 
Our results demonstrated a small association between negative LLETZ and women with high grade 
cytology and a TZ type 3. Currently, it appears safer at present to treat these women as more than 
70% will harbour high grade CIN. The caveat to this recommendation is in women whose interval 
from referral cytology to colposcopy is greater than three months; repeat cytology (cytobrush and 
broom) in these cases may reduce false positives by as 40% of biopsy proven CIN2 and 32% of biopsy 
proven CIN3 have been shown to regress.34  
 
There are currently no UK recommendations to guide the management of a TZ type 3 in the 
presence of low grade cytology21. The American Society for Lower Genital Tract Disorders 
recommends that women with low grade cytology should not be treated unless high grade CIN is 
detected on biopsy35. As endocervical curettage is not routine practise in the UK, it is difficult to 
implement this policy and provide histological confirmation in the presence of a TZ type 3. Our data 
suggests a low risk of CIN2+ in this cohort and these women may benefit from cytological follow up 
to avoid negative LLETZ histology and the increased risks of preterm labour and cervical stenosis. 
 
Conclusion: 
To reduce screen false positives and subsequent negative LLETZ histology, future research should 
focus on improving the specificity of CIN screening; this should include the use of biomarkers that 
detect HPV-transforming infections, HPV genotyping and the use of techniques which sample an 
endocervical transformation zone. Furthermore, prospective studies should assess the progression 
rate of CIN in women with low grade dyskaryosis and a TZ type 3 who are managed with cytological 
follow up. The outcome of these studies will help form the basis of treatment recommendations for 
women with low grade cytology, a TZ type 3 and a high risk HPV screening result. 
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Table 1: Description of patient and clinical characteristics of the study sample and a 
comparison between the pre and post HPV testing cohorts. 
 Combined 
cohorts 
(n=802) 
Pre-HPV 
cohort 
(n=401) 
Post-HPV 
cohort 
(n=401) 
p-value 
Patient Characteristics: 
AGE: 
<30 years 
31-40 years 
41-50 years 
51+ years 
 
350 (43.6%) 
275 (34.2%) 
127 (15.8%) 
50 (6.2%) 
 
163 (40.7%) 
155 (38.7%) 
65 (16.2%) 
18 (4.4%) 
 
187 (46.7%) 
120 (29.9%) 
62 (15.5%) 
32 (7.9%) 
 
0.018 
PARITY: 
None 
1 
2+ 
 
385 (48.0%) 
163 (20.3%) 
254 (31.7%) 
 
195 (48.6%) 
68 (16.9%) 
138 (34.4%) 
 
190 (47.9%) 
95 (23.7%) 
116 (28.9%) 
 
0.04 
CONTRACEPTIVE: 
None 
Oestrogen 
Progesterone 
 
295 (36.8%) 
177 (22.1%) 
330 (41.1%) 
 
173 (40.1%) 
79 (19.7%) 
149 (39.9%) 
 
122 (30.4%) 
98 (24.4%) 
181 (45.1%) 
 
0.009 
SMOKING: 
None 
1-5 / day 
6-10 / day 
11+ / day 
 
530 (66.8%) 
81 (10.1%) 
91 (11.3%) 
100 (12.4%) 
 
251 (62.6%) 
41 (10.2%) 
52 (12.9%) 
57 (14.2%) 
 
279 (69.6%) 
40 (9.9%) 
39 (9.7%) 
43 (10.7%) 
 
0.15 
Clinical Characteristics: 
Referral Cytology: 
Low Grade 
High Grade 
 
232 (28.9%) 
570 (71.2%) 
 
125 (31.2%) 
276 (68.8%) 
 
107 (26.7%) 
294 (73.3%) 
 
0.161 
Cytology to Colposcopy Interval: 
0-4 weeks 
5-8 weeks 
9+ weeks 
 
385 (48%) 
291 (36.3%) 
126 (15.7%) 
 
134 (33.4%) 
183 (45.6%) 
84 (20.9%) 
 
251 (62.6%) 
108 (26.9%) 
42 (10.8%) 
 
<0.001 
TZ type: 
Unsatisfactory 
Satisfactory 
 
130 (16.2%) 
672 (83.9%) 
 
58 (14.5%) 
343 (85.5%) 
 
72 (17.9%) 
329 (82.1%) 
 
0.179 
Excision Depth: 
0-6mm 
7+ mm 
 
339 (42.2%) 
463 (57.7%) 
 
190 (47.4%) 
211 (57.6%) 
 
149 (37.2%) 
252 (62.8%) 
 
0.003 
TZ included in LLETZ: 
Yes 
No 
 
790 (98.5%) 
12 (1.5%) 
 
397 (99%) 
4 (1%) 
 
393 (98%) 
8 (12%) 
 
0.38 
Limiting histological factors: 
No 
Yes 
 
578 (72.1%) 
224 (27.9%) 
 
283 (70.6%) 
118 (29.4%) 
 
295 (73.6%) 
106 (26.4%) 
 
0.34 
Criteria for LLETZ 
Punch biopsy: 
Persistent CIN1 for >24 months 
CIN2 
CIN3 
cGIN 
 
74 (9.2%) 
156 (19.5%) 
138 (17.2%) 
 11 (1.3%) 
179 (44.6%) 
40 (9.9%) 
79 (19.7%) 
56 (13.9%) 
4 (1%) 
200 (49.9%) 
34 (8.5%) 
77 (19.2%) 
82 (20.4%) 
7 (1.7%) 
 
0.16 
 
No prior histology: 
High grade cytology & TZ type 3 
High grade cytology & HG colposcopy 
Low grade cytology >12m & TZ type 3 
 
82 (10.2%) 
283 (35.3%) 
58 (7.2%) 
222 (55.4%) 
24 (5.9%) 
163 (40.6%) 
35 (8.7%) 
201 (50.1%) 
58 (14.5%) 
120 (29.9%) 
23 (5.7%) 
 
<0.001 
LLETZ Histological Characteristics 
CIN1 
CIN2 
CIN3 
85 (10.5%) 
182 (22.7%) 
351 (43.7%) 
37 (9.2 %) 
98 (24.4%) 
162 (40.3%) 
48 (11.9%) 
84 (20.9%) 
189 (47.1%) 
0.16 
cGIN 
Invasion 
28 (3.4%) 
25 (3.1%) 
13 (3.2%) 
11 (2.7%) 
15 (3.7%) 
14 (3.4%) 
0.86 
Negative Histology 134 (16.7%) 80 (19.9%) 54 (13.4%) 0.016 
Table 2: Criteria for treatment in women with negative LLETZ histology in the pre- 
and post-HPV testing cohorts. 
 
 Pre-HPV  
testing cohort  
(n=80) 
Post-HPV 
testing cohort 
(n=54) 
p-value 
Previous Punch Biopsy: 
Persistent CIN1 for >24 months 
CIN2 
CIN3 
 
10 (12.5%) 
12 (15%) 
18 (22.5%) 
 
6 (11.1%) 
5 (9.3%) 
13 (24.1%) 
 
0.69 
No confirmatory histology       
(See and Treat LLETZ): 
High grade cytology & TZ type 3 
High grade cytology & HG colposcopy 
Low grade cytology >12m & TZ type 3 
 
 
9 (11.2%) 
4 (5%) 
25 (31.2%) 
 
 
7 (12.9%) 
3 (5.5%) 
22 (40.7%) 
 
 
0.97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: The association between HPV screening and the risk of negative LLETZ 
(n=802). The crude association is provided along with the association after adjusting 
for each potential confounder and a final model adjusting for all possible 
confounders. 
 Relative Risk 
(RR) 
95% CI P-
value 
Unadjusted: 0.68 0.49 – 0.93 0.015 
Adjusted for:    
Age 0.66 0.48 – 0.90 0.010 
Smoking 0.68 0.49 – 0.94 0.018 
Contraceptive 0.71 0.51 – 0.97 0.031 
Parity 0.70 0.51 – 0.95 0.024 
Referral Cytology 0.69 0.50 – 0.94 0.02 
Cytology to Colposcopy 
Interval 
0.83 0.60 – 1.15 0.26 
TZ type 0.62 0.46 – 0.84 0.002 
Biopsy result 0.66 0.48 – 0.90 0.01 
Excision Depth 0.69 0.50 – 0.94 0.021 
Limiting histological factors 0.69 0.50 – 0.94 0.019 
    
Adjusted for all potential 
confounders: 
0.75 0.55 – 0.97 0.047 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Risk factors for negative LLETZ in women who underwent HPV screening 
(n=401). 
 Unadjusted associations Adjusted final model† 
RR 95% CI p RR 95% CI p 
Age: 
≤30 
31 to 40 
41 to 50 
51+ 
 
Ref* 
1.36 
3.02 
2.92 
 
 
0.69 - 2.69 
1.60 - 5.67 
1.36 – 6.26 
 
 
0.37 
0.001 
0.006 
   
Parity 
0 
1 
2+ 
 
Ref* 
1.25 
2.87 
 
 
0.59 - 2.65 
1.62 – 5.07 
 
 
0.6 
<0.001 
 
 
1.28 
2.13 
 
 
0.56 - 2.90 
1.13 - 4.01 
 
 
0.55 
0.02 
Smoking 
No 
Yes 
 
Ref* 
1.35 
 
 
0.81 – 2.24 
 
 
0.26 
   
Contraceptive: 
None 
COCP 
Progesterone 
 
Ref* 
0.40 
0.77 
 
 
0.18 – 0.89 
0.44 - 1.30 
 
 
0.025 
0.32 
   
Cytology 
High Grade 
Low Grade 
 
Ref* 
3.19 
 
 
1.95 – 5.21 
 
 
<0.001 
 
 
3.60 
 
 
2.18 – 5.97 
 
 
<0.001 
Cytology to Colp Interval: 
0 to 4 weeks 
5 to 8 weeks 
9+ weeks 
 
Ref* 
1.61 
2.30 
 
 
0.92 - 2.81 
1.20 - 4.42 
 
 
0.095 
0.092 
   
Colposcopy 
Satisfactory 
Unsatisfactory 
 
Ref* 
3.94 
 
 
2.46 - 6.31 
 
 
<0.001 
 
 
2.88 
 
 
1.76 – 4.72 
 
 
<0.001 
Biopsy prior to LLETZ: 
None 
CIN1 >24 months 
CIN2 
CIN3 
 
Ref* 
1.15 
0.25 
1.03 
 
 
0.52 – 2.54 
0.08 – 0.80 
0.57 – 1.86 
 
 
0.7 
0.02 
0.9 
 
 
0.68 
0.25 
0.92 
 
 
0.31 – 1.50 
0.08 – 0.79 
0.49 – 1.73 
 
 
0.34 
0.018 
0.8 
Excision Depth 
≥7mm 
 
1.09 
 
0.65 – 1.83 
 
0.70 
   
Limiting Factors 
Present 
 
1.17 
 
0.68 – 2.01 
 
0.60 
   
 
*Ref = Reference category 
† The final model was robust to choice of selection method (forward or backwards stepwise selection) 
and choice of cut off for entry to, or removal from the model (p<0.05 or p<0.1).   
 
 
 
 
 
Supplementary Table S1: Association between negative LLETZ (the outcome) and 
exposure to different variables. 
 
Exposure 
Negative LLETZ 
No (n = 668)                       Yes (n = 134) 
  
P-value 
HPV Testing: 
Yes 
No 
 
347 (51.9%) 
321 (48.1%) 
 
54 (40.3%) 
80 (59.7%) 
 
0.013 
Age: 
<30 years 
31-40 years 
41-50 years 
51+ years 
 
312 (46.7%) 
231 (34.6%) 
92 (13.8%) 
33 (4.9%) 
 
38 (16.2%) 
44 (32.8%) 
35 (26.1%) 
17 (12.7%) 
 
<0.001 
Smoking: 
None 
1-5 / day 
6-10 / day 
11+ / day 
 
446 (66.7%) 
61 (9.1%) 
77 (11.5%) 
84 (12.6%) 
 
84 (62.7%) 
20 (14.9%) 
14 (10.4%) 
16 (11.9%) 
 
0.246 
Parity: 
None 
1 
2+ 
 
336 (50.3%) 
143 (21.4%) 
189 (28.3%) 
 
49 (36.6%) 
20 (14.9%) 
65 (48.5%) 
 
<0.001 
Contraceptive: 
None 
Oestrogen 
Progesterone 
 
221 (33.1%) 
154 (23.5%) 
293 (43.9%) 
 
74 (55.2%) 
23 (17.2%) 
37 (27.6%) 
 
<0.001 
Referral Cytology: 
Low Grade 
High Grade 
 
165 (24.7%) 
503 (75.3%) 
 
67 (50%) 
67 (50%) 
 
<0.001 
Cytology to Colposcopy 
Interval: 
0-4 weeks 
5-8 weeks 
9+ weeks 
 
 
345 (51.6%) 
234 (35.0%) 
89 (13.3%) 
 
 
40 (29.9%) 
57 (42.5%) 
37 (27.6%) 
 
 
<0.001 
TZ type: 
Unsatisfactory 
Satisfactory 
 
67 (10%) 
601 (90%) 
 
63 (47%) 
71 (53%) 
 
<0.001 
Biopsy prior to LLETZ 
None 
CIN1 
CIN2 
CIN3 
cGIN 
 
353 (52.8%) 
58 (8.8%) 
139 (20.8%) 
107 (16.0%) 
11 (1.6%) 
 
70 (52.2%) 
16 (11.9%) 
17 (12.7%) 
31 (23.1%) 
0 (0%) 
 
0.03 
Excision Depth: 
0-6mm 
7+ mm 
 
275 (41.2%) 
393 (58.8%) 
 
64 (47.8%) 
70 (52.2%) 
 
0.158 
TZ included in LLETZ: 
Yes 
No 
 
664 (99.4%) 
4 (0.6%) 
 
126 (94.6%) 
8 (5.4%) 
 
<0.001 
Limiting Factors: 
No 
Yes 
 
497 (74.4%) 
171 (25.6%) 
 
81 (60.4%) 
53 (39.6%) 
 
0.001 
 
